The distribution of the anticancer drug doxorubicin in relation to blood vessels in solid tumors

Clinical Cancer Research

Volumn 11, Issue 24, 2005, Pages 8782-8788

  Primeau, Andrew J ^a   Rendon, Augusto ^a   Hedley, David ^a   Lilge, Lothar ^a   Tannock, Ian F ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 NITRO 1H IMIDAZOL 1 YL) N (2,2,3,3,3 PENTAFLUOROPROPYL)ACETAMIDE; ANTINEOPLASTIC AGENT; CD31 ANTIGEN; DOXORUBICIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL; CANCER CELL; CANCER RESISTANCE; CARDIOVASCULAR SYSTEM; CONTROLLED STUDY; DRUG DISTRIBUTION; HUMAN; HUMAN CELL; HYPOXIA; IMMUNOFLUORESCENCE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SOLID TUMOR;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; BLOOD VESSELS; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; HUMANS; MICE; MICROSCOPY; NEOPLASM TRANSPLANTATION; NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 29344443251     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-1664     Document Type: Article

References (21)

1. Sutherland RM, Eddy HA, Bareham B, Reich K, Vanantwerp D. Resistance to Adriamycin in multicellular spheroids. Int J Radiat Oncol Biol Phys 1979;5: 1225-30.
2. Hicks KO, Ohms SJ, van Zijl PL, Denny WA, Hunter PJ, Wilson WR. An experimental and mathematical model for the extravascular transport of a DNA intercalator in tumours. Br J Cancer 1997;76: 894-903.
3. Tunggal JK, Cowan DSM, Shaikh H, Tannock IF. Penetration of anticancer drugs through solid tissue: a factor that limits the effectiveness of chemotherapy for solid tumours. Clin Cancer Res 1999;5: 1583-6.
4. Tannock IF, Lee CM, Tunggal JK, Cowan DS, Egorin MJ. Limited penetration of anticancer drugs through tumor tissue: a potential cause of resistance of solid tumors to chemotherapy. Clin Cancer Res 2002;8: 878-84.
5. Huxham LA, Kyle AH, Baker JH, Nykilchuk LK, Minchinton AI. Microregional effects of gemcitabine in HCT-116 xenografts. Cancer Res 2004;64: 6537-41.
6. Jain RK. The next frontier of molecular medicine: delivery of therapeutics. Nat Med 1998;4:655-7.
7. Tong RT, Boucher Y, Kozin SV, Winkler F, Hicklin DJ, Jain RK. Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res 2004;64:3731-6.
8. Winkler F, Kozin SV, Tong RT, et al. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 2004;6:553-63.
9. Lankelma J, Dekker H, Luque FR, et al. Doxorubicin gradients in human breast cancer. Clin Cancer Res 1999;5:1703-7.
10. Romijn JC. Growth of tumor cells with different sensitivities for murine natural killer cells in young and adult athymic nude mice. Exp Cell Biol 1985;53: 24-31.
11. Tannock IF. In vivo interaction of anticancer drugs with misonidazole or metronidazole: methotrexate, 5-fluorouracil and Adriamycin. Br J Cancer 1980;42: 861-70.
12. Less JR, Skalak TC, Sevick EM, Jain RK. Microvascular architecture in a mammary carcinoma: branching patterns and vessel dimensions. Cancer Res 1991;51: 265-73.
13. Ouar Z, Bens M, Vignes C, et al. Inhibitors of vacuolar H+-ATPase impair the preferential accumulation of daunomycin in lysosomes and reverse the resistance to anthracyclines in drug-resistant renal epithelial cells. Biochem J 2003; 370:185-93.
14. Bernardini N, Giannessi F, Blanchi F, et al. Comparative activity of doxorubicin and its major metabolite, doxorubicinol, on V79/AP4 fibroblasts: a morphofunctional study. Exp Mol Pathol 1991;55: 238-50.
15. Davis AJ, Tannock IF. Repopulation of tumour cells between cycles of chemotherapy: a neglected factor. Lancet Oncol 2000;1:86-93.
16. Kim JJ, Tannock IF. Repopulation of cancer cells during radiotherapy and chemotherapy: an important cause of treatment failure. Nat Rev Cancer 2005;5: 516-25.
17. Errington RJ, Ameer-Beg SM, Vojnovic B, Patterson LH, Zloh M, Smith PJ. Advanced microscopy solutions for monitoring the kinetics and dynamics of drug-DNA targeting in living cells. Adv Drug Deliv Rev 2005;57: 153-67.
18. Oldenburg J, Oldenburg J, Begg AC, et al. Characterization of resistance mechanisms to cis-diaminedichloroplatinum(II) in three sublines of the CC531colon adenocarcinoma cell line in vitro. Cancer Res 1994; 54:487-93.
19. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005;307:58-62.
20. Kerbel RS, St Croix B, Florenes VA, Rak J. Induction and reversal of cell adhesion-dependent multicellular drug resistance in solid breast tumors. Hum Cell 1996; 9:257-64.
21. St Croix B, Man S, Kerbel RS. Reversal of intrinsic and acquired forms of drug resistance by hyaluronidase treatment of solid tumors. Cancer Lett 1998;131: 35-44.